Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.

PubWeight™: 5.30‹?› | Rank: Top 1%

🔗 View Article (PMID 21303976)

Published in Cancer Res on February 08, 2011

Authors

Marie Tosolini1, Amos Kirilovsky, Bernhard Mlecnik, Tessa Fredriksen, Stéphanie Mauger, Gabriela Bindea, Anne Berger, Patrick Bruneval, Wolf-Herman Fridman, Franck Pagès, Jérôme Galon

Author Affiliations

1: INSERM, Integrative Cancer Immunology Team, INSERM U872, Paris, France.

Associated clinical trials:

NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer (MAYA) | NCT03832621

Articles citing this

(truncated to the top 100)

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78

Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41

The consensus molecular subtypes of colorectal cancer. Nat Med (2015) 4.35

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00

Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90

Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62

Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med (2013) 2.50

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47

Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A (2014) 2.12

Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat Biotechnol (2014) 2.10

Microbes, microbiota, and colon cancer. Cell Host Microbe (2014) 2.06

Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity (2014) 1.87

Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 1.81

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78

CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell (2013) 1.71

Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth. Nat Cell Biol (2015) 1.63

Regulatory T-cell Response to Enterotoxigenic Bacteroides fragilis Colonization Triggers IL17-Dependent Colon Carcinogenesis. Cancer Discov (2015) 1.57

HIF transcription factors, inflammation, and immunity. Immunity (2014) 1.55

Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol (2013) 1.54

An immunologic portrait of cancer. J Transl Med (2011) 1.50

γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity (2014) 1.49

What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer (2017) 1.39

B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One (2013) 1.38

Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest (2014) 1.33

Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest (2013) 1.33

Th17 cells in cancer: the ultimate identity crisis. Front Immunol (2014) 1.33

Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci (2012) 1.32

Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother (2013) 1.31

Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene (2014) 1.30

Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A (2012) 1.30

The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology (2012) 1.26

Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest (2015) 1.24

Small molecule inhibitors of RORγt: targeting Th17 cells and other applications. Eur J Immunol (2012) 1.24

Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One (2013) 1.22

Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol (2013) 1.17

Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther (2012) 1.15

Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med (2016) 1.11

Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res (2011) 1.10

Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol (2012) 1.10

Emerging cytokine networks in colorectal cancer. Nat Rev Immunol (2015) 1.09

The role and regulation of human Th17 cells in tumor immunity. Am J Pathol (2012) 1.09

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol (2011) 1.09

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer (2013) 1.06

Basic principles of tumor-associated regulatory T cell biology. Trends Immunol (2012) 1.05

Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep (2012) 1.05

Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med (2012) 1.04

Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol (2013) 1.04

STAT3 activation: A key factor in tumor immunoescape. JAKSTAT (2013) 1.04

TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer (2013) 1.04

Th17 cells and Tregs: unlikely allies. J Leukoc Biol (2014) 1.03

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med (2013) 1.03

Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci (2011) 1.01

Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol (2013) 1.00

Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99

Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. Front Genet (2013) 0.99

The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron (2012) 0.98

Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem (2012) 0.98

Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology (2014) 0.98

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res (2014) 0.97

High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS One (2013) 0.97

β-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. Sci Transl Med (2014) 0.96

Immune system: a double-edged sword in cancer. Inflamm Res (2013) 0.95

The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics (2012) 0.95

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol (2016) 0.94

Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology (2015) 0.94

Gut microbiome and colorectal adenomas. Cancer J (2014) 0.94

Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene (2015) 0.93

Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol (2013) 0.92

Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. Proc Natl Acad Sci U S A (2014) 0.92

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J Natl Cancer Inst (2016) 0.91

Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different. Virchows Arch (2014) 0.91

Digital pattern recognition-based image analysis quantifies immune infiltrates in distinct tissue regions of colorectal cancer and identifies a metastatic phenotype. Br J Cancer (2013) 0.90

From mice to humans: developments in cancer immunoediting. J Clin Invest (2015) 0.90

Microbiota impact on the epigenetic regulation of colorectal cancer. Trends Mol Med (2013) 0.90

Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget (2014) 0.89

Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ (2014) 0.89

Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci (2014) 0.89

Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-κB/ZEB1 signal pathway. Am J Cancer Res (2015) 0.89

Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget (2015) 0.89

Obesity accelerates Helicobacter felis-induced gastric carcinogenesis by enhancing immature myeloid cell trafficking and TH17 response. Gut (2013) 0.89

Dancing with the Stars: How Choreographed Bacterial Interactions Dictate Nososymbiocity and Give Rise to Keystone Pathogens, Accessory Pathogens, and Pathobionts. Trends Microbiol (2016) 0.89

The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology (2015) 0.89

Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget (2015) 0.88

Th17 Cell Plasticity and Functions in Cancer Immunity. Biomed Res Int (2015) 0.88

Inflammatory networks underlying colorectal cancer. Nat Immunol (2016) 0.88

Role of TH17 cytokines in the control of colorectal cancer. Oncoimmunology (2013) 0.87

Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol (2016) 0.87

Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol (2012) 0.87

Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression. Pathol Oncol Res (2011) 0.87

The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis. Int J Mol Sci (2016) 0.86

Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis. PLoS One (2014) 0.86

Redundant Innate and Adaptive Sources of IL17 Production Drive Colon Tumorigenesis. Cancer Res (2016) 0.85

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl Acad Sci U S A (2016) 0.85

Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma. PLoS One (2011) 0.85

Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers. World J Gastroenterol (2012) 0.85

Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol (2016) 0.84

Articles by these authors

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54

Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63

The Medicago genome provides insight into the evolution of rhizobial symbioses. Nature (2011) 4.94

Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol (2003) 4.91

Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2012) 4.85

Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97

Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet (2006) 3.65

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96

Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90

Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88

The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79

PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest (2012) 2.61

Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res (2006) 2.56

PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43

Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 2.37

Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet (2005) 2.36

The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res (2007) 2.34

Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas. Am J Surg Pathol (2014) 2.23

Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int (2010) 2.22

Cardiac stem cells in the real world. J Thorac Cardiovasc Surg (2008) 2.19

Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16

Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med (2010) 2.15

Sleeve gastrectomy severe complications: is it always a reasonable surgical option? Obes Surg (2013) 2.08

Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium? Interact Cardiovasc Thorac Surg (2007) 2.07

Tracheal regeneration: evidence of bone marrow mesenchymal stem cell involvement. J Thorac Cardiovasc Surg (2012) 2.07

A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest (2010) 2.06

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest (2010) 2.02

Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology (2009) 2.01

KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet (2012) 1.93

Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res (2011) 1.91

High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol (2007) 1.90

CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics (2013) 1.82

FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol (2007) 1.81

High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med (2003) 1.80

Parietal podocytes in normal human glomeruli. J Am Soc Nephrol (2006) 1.79

Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. J Am Coll Cardiol (2004) 1.79

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant (2008) 1.76

Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant (2013) 1.71

Natural immunity to cancer in humans. Curr Opin Immunol (2010) 1.69